SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. Logo

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

A contract research organization providing comprehensive drug development services.

2395 | T

Overview

Corporate Details

ISIN(s):
JP3379950003
LEI:
Country:
Japan
Address:
鹿児島市宮之浦町2438番地

Description

Shin Nippon Biomedical Laboratories, Ltd. (SNBL) is a contract research organization (CRO) providing comprehensive drug development services. Established in 1957 as Japan's first CRO, the company supports pharmaceutical clients throughout the development lifecycle, from preclinical safety studies to clinical trial management. SNBL offers a full suite of services, including safety assessments and clinical data management. A key area of innovation is its proprietary nasal drug delivery technology, SMART (Simple MucoAdhesive Release Technology). The company's mission is to contribute to medical advancement and alleviate patient suffering by supporting the creation of new pharmaceuticals.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-07-14 08:10
公開買付報告書
Japanese 30.0 KB
2022-06-29 02:57
訂正公開買付届出書
Japanese 165.0 KB
2022-06-29 02:11
内部統制報告書-第49期(令和3年4月1日-令和4年3月31日)
Japanese 22.7 KB
2022-06-29 02:10
確認書
Japanese 8.3 KB
2022-06-29 02:09
有価証券報告書-第49期(令和3年4月1日-令和4年3月31日)
Japanese 1.9 MB
2022-06-27 07:24
訂正公開買付届出書
Japanese 173.5 KB
2022-06-02 04:13
公開買付届出書
Japanese 340.6 KB
2022-02-02 08:35
四半期報告書-第49期第3四半期(令和3年10月1日-令和3年12月31日)
Japanese 179.0 KB
2021-11-02 07:29
四半期報告書-第49期第2四半期(令和3年7月1日-令和3年9月30日)
Japanese 218.4 KB
2021-08-04 08:10
四半期報告書-第49期第1四半期(令和3年4月1日-令和3年6月30日)
Japanese 177.0 KB
2021-06-30 09:48
内部統制報告書-第48期(令和2年4月1日-令和3年3月31日)
Japanese 22.7 KB
2021-06-30 09:48
確認書
Japanese 8.3 KB
2021-06-30 09:47
有価証券報告書-第48期(令和2年4月1日-令和3年3月31日)
Japanese 1.5 MB
2021-02-05 07:21
四半期報告書-第48期第3四半期(令和2年10月31日-令和2年12月31日)
Japanese 160.1 KB
2020-11-06 07:10
四半期報告書-第48期第2四半期(令和2年7月1日-令和2年9月30日)
Japanese 193.6 KB

Automate Your Workflow. Get a real-time feed of all SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.